XLV241220C120000
- 24.62
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
The Health Care Select Sector SPDR Fund To Go Ex-Dividend On December 23rd, 2024 With 0.62165 USD Dividend Per Share
Friday Market Rebounds Some of Weeks Loss | Wall Street Today
Pfizer Gets FDA Accelerated Approval for Braftovi
FDA Grants Accelerated Approval To Encorafenib With Cetuximab And MFOLFOX6 For Metastatic Colorectal Cancer With A BRAF V600E Mutation
Government Shutdown Threat: Stocks Wobble, Holiday Travel And Paychecks Could Face Delays: What You Need To Know
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
J.P. Morgan's Top Healthcare Stocks for 2025
Merck Downgraded by BMO Over Keytruda Concerns
RxSight Cut to Hold at Stifel on Competition Concerns
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
5 High-Flying Stocks In Dan Loeb's Portfolio: Cinemark, Corpay, Amazon Lead
Sector Update: Health Care Stocks Mixed Premarket Friday
Today's Pre-Market Movers and Top Ratings | FDX, NKE, NVO and More
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Focus on Upcoming Inflation Report
Leading And Lagging Sectors For December 20, 2024
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Novo Nordisk New Obesity Therapy CagriSema Outperforms Semaglutide in Phase 3 Trial
Merck & Co Analyst Ratings